The Food and Drug Administration (FDA) has approved Kynmobi™ (apomorphine hydrochloride; Sunovion) for the acute, intermittent treatment of off episodes in patients with Parkinson disease (PD).
The Food and Drug Administration (FDA) has approved Ongentys® (opicapone; Neurocrine Biosciences) as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease (PD) experiencing “off” episodes.
Change in total Unified Parkinson’s Disease Rating Scale score similar for isradipine versus placebo.
Identification of at-risk populations varies by scale used, which could impact clinical practice.
The FDA has approved an expanded indication for the Infinity™ Deep Brain Stimulation (DBS) system (Abbott) to include targeting the internal globus pallidus, which may lead to symptom improvement in patients with Parkinson disease.
The FDA has accepted for review the resubmitted New Drug Application (NDA) for apomorphine sublingual film (APL-130277; Sunovion) for the treatment of OFF episodes in patients with Parkinson disease (PD).
The Food and Drug Administration (FDA) has granted Breakthrough Device designation to the RightEye Vision System, a device that measures and analyzes involuntary eye movements to aid in the assessment of Parkinson disease (PD). In 2018, the FDA granted 510(k) clearance to the portable eye-tracking system to help diagnose and monitor health and vision issues.…
Apomorphine sublingual film is designed to be a fast-acting on-demand treatment for all types of motor OFF episodes.
The FDA has granted Fast Track designation to neflamapimod (EIP Pharma) for the treatment of dementia with Lewy bodies (DLB).
Nourianz is now available as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson disease (PD) experiencing “off” episodes.
